BioArctic AB Share Price

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 16:25:00 30/05/2024 BST 5-day change 1st Jan Change
228.1 SEK +3.31% Intraday chart for BioArctic AB -3.43% -15.83%

Financials

Sales 2024 * 535M 50.54M 3.97B Sales 2025 * 1.04B 98.53M 7.74B Capitalization 19.5B 1.84B 145B
Net income 2024 * 34M 3.21M 252M Net income 2025 * 433M 40.88M 3.21B EV / Sales 2024 * 34.7 x
Net cash position 2024 * 946M 89.28M 7.01B Net cash position 2025 * 1.21B 114M 8.96B EV / Sales 2025 * 17.5 x
P/E ratio 2024 *
586 x
P/E ratio 2025 *
45.1 x
Employees 88
Yield 2024 *
-
Yield 2025 *
-
Free-Float 44.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.31%
1 week-3.43%
Current month+15.59%
1 month+15.59%
3 months+2.83%
6 months-3.01%
Current year-15.83%
More quotes
1 week
220.00
Extreme 220
240.60
1 month
189.90
Extreme 189.9
243.00
Current year
175.00
Extreme 175
288.40
1 year
175.00
Extreme 175
392.00
3 years
66.70
Extreme 66.7
392.00
5 years
47.00
Extreme 47
392.00
10 years
20.40
Extreme 20.4
392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 31/12/12
Founder 77 23/01/03
Founder 75 23/01/03
Members of the board TitleAgeSince
Chairman 70 31/12/16
Director/Board Member 58 31/05/23
Director/Board Member 56 -
More insiders
Date Price Change Volume
30/05/24 225.6 +2.17% 80 069
29/05/24 220.8 -5.07% 103,249
28/05/24 232.6 +2.02% 134,366
27/05/24 228 -4.36% 127,794
24/05/24 238.4 +2.14% 139,773

Delayed Quote Nasdaq Stockholm, May 30, 2024 at 04:10 pm

More quotes
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
220.8 SEK
Average target price
368 SEK
Spread / Average Target
+66.67%
Consensus
  1. Stock Market
  2. Equities
  3. BIOA B Stock